Thermo Fisher Scientific Inc. (NYSE:TMO) is among the best stocks in each sector in 2026. On February 9, Matt Larew, an analyst at William Blair, reiterated a Buy rating on Thermo Fisher Scientific Inc. (NYSE:TMO). Blair is among the 90% of analysts bullish on the stock, with the remaining 10% neutral. The 1-year median price target of $670 translates to an upside potential of 29.73%.
On January 30, Stifel maintained its Buy rating and $700 price target on Thermo Fisher Scientific Inc. (NYSE:TMO). This reaffirmation was attributed to the company’s solid performance at the end of the past year. According to the firm, the company is one of the few companies in the healthcare sector that hadn’t disclosed results in advance before delivering a “solid beat” for the last quarter.
Perhaps even more noteworthy is Thermo Fisher Scientific Inc. (NYSE:TMO)’s exposure to the biopharma segment, which the firm believes could accelerate growth into the mid-single digits range. The segment accounts for nearly 60% of the giant’s revenues. Stifel is positive about the company’s potential for high-single-digit EPS growth, with further upside expected from the Clario acquisition, once it completes.
Thermo Fisher Scientific Inc. (NYSE:TMO) is a Massachusetts-based provider of a range of solutions, including life sciences, analytical instruments, and specialty diagnostics. Incorporated in 1956, the company offers its products and services through third-party distributors, electronic commerce, and a direct sales force.
While we acknowledge the potential of TMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. Follow Insider Monkey on Google News.
